Aim: Compare weight changes between people living with HIV-1 (PLWH) at high risk of weight gain
(females, Blacks or Hispanics) switching from an integrase strand transfer inhibitor (INSTI) to a protease
inhibitor (PI) or another INSTI. Materials & methods: Mean weight changes from pre-switch to up-to-
12 months post-switch were retrospectively compared between PLWH switching to a PI or INSTI. Results:
356 PLWH were eligible. At 9- and 12-month post-switch, weight increases were observed for INSTI
(weight: +1.55 kg and +1.59 kg), while decreases were observed for PI (-0.23 kg and -1.59 kg); differences
between cohorts widened over time. Conclusion: These data suggest that switching off an INSTI may be
a management tool to mitigate or reverse weight gain.
This study was funded by Janssen Scientific Affairs, LLC. The study sponsor was involved in several aspects of the research, including the study design, the interpretation of data, thewriting of themanuscript and the decision to submit themanuscript for publication. B Emond, A Shah, M Vermette-Laforme, C Rossi and M-H Lafeuille are employees of Analysis Group, Inc., a company that provided consulting services to Janssen Scientific Affairs, LLC for the development and conduct of this study and manuscript. BK Bookhart, D Anderson and P Donga are employees of Janssen Scientific Affairs, LLC and are stockholders of Johnson & Johnson. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing and editorial assistance were provided by K Milbers, a former employee and F Chik, a current employee of Analysis Group, Inc., a consulting company that has provided paid consulting services to Janssen Scientific Affairs, LLC, which funded the development and conduct of this study and manuscript.